


From: **Pablocruzin** pablocruzin@shaw.ca 
Subject:
Date: January 10, 2022 at 12:20 PM
To:



From FDA Presentation - VRBPAC-10.22.20-Meeting-Presentation-COVID19-CBER-Monitoring-Vaccine (See Page 16 Pfizer Adverse Events).pdf

FDA Safety Surveillance of COVID-19 Vaccines :
DRAFT Working list of possible adverse event outcomes
*****Subject to change*****

- Guillain-Barré syndrome
- Acute disseminated encephalomyelitis
- Transverse myelitis
- Encephalitis/myelitis/encephalomyelitis/
meningoencephalitis/meningitis/
encepholopathy
- Convulsions/seizures
- Stroke
- Narcolepsy and cataplexy
- Anaphylaxis
- Acute myocardial infarction
- Myocarditis/pericarditis
- Autoimmune disease
- Deaths
- Pregnancy and birth outcomes
- Other acute demyelinating diseases
- Non-anaphylactic allergic reactions
- Thrombocytopenia
- Disseminated intravascular coagulation
- Venous thromboembolism
- Arthritis and arthralgia/joint pain
- Kawasaki disease
- Multisystem Inflammatory Syndrome
in Children
- Vaccine enhanced disease

Regards,

Paul C. Bush
pbush001@me.com
(C) 604 807 8075

“There is no greater tyranny than that which is perpetrated under the shield of the law and in the name of justice.”